GLP-1 Refractory Obesity Is Associated with Inferior Weight Loss After Bariatric Surgery and a Distinct Hepatic Mitochondrial Phenotype

Verdict. Objectives To characterize the hepatic histological, ultrastructural, and molecular phenotype of GRO at bariatric surgery, determine its recovery following surgery, and identify preoperative hepatic biomarkers associated with postoperative weight loss. It intersects mitochondrial stress/dysfunction themes (mitochondrial dysfunction; OXPHOS / ETC; disease context).

What the authors report

Background: Glucagon-like peptide-1 receptor agonists (GLP1 RAs) are first-line pharmacotherapy for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD); however, 20% to 35% of patients fail to achieve clinically meaningful weight loss despite guideline-directed therapy. Whether this GLP1 refractory obesity (GRO) phenotype is associated with distinct hepatic molecular abnormalities or influences bariatric surgical outcomes remains unknown.

Key results stated in the abstract include the following. Objectives To characterize the hepatic histological, ultrastructural, and molecular phenotype of GRO at bariatric surgery, determine its recovery following surgery, and identify preoperative hepatic biomarkers associated with postoperative weight loss. GRO was defined as Keywords: GLP1 receptor agonist refractoriness; bariatric surgery; hepatic steatosis; MASLD; AMPK; pCREB; mitochondrial dysfunction; OXPHOS; weight loss outcomes; biomarker

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to OXPHOS, metabolism, therapeutics, structural biology. It is relevant to mitochondrial dysfunction discourse because the abstract invokes mitochondrial dysfunction, OXPHOS / ETC, disease context, systemic metabolic stress. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. OXPHOS/ETC involvement, if confirmed, would place the work in the core of bioenergetic pathophysiology rather than peripheral organelle biology. Server: medrxiv. Posted 2026-08-06. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

Background: Glucagon-like peptide-1 receptor agonists (GLP1 RAs) are first-line pharmacotherapy for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD); however, 20% to 35% of patients fail to achieve clinically meaningful weight loss despite guideline-directed therapy. Methods Intraoperative liver biopsies were obtained from lean controls (n=3), GLP1 naive obese patients (GNO; n=10), and GLP1-refractory obese patients (GRO; n=10) undergoing Roux-en-Y gastric bypass.

Principal findings

1. Objectives To characterize the hepatic histological, ultrastructural, and molecular phenotype of GRO at bariatric surgery, determine its recovery following surgery, and identify preoperative hepatic biomarkers associated with postoperative weight loss.
2. GRO was defined as Keywords: GLP1 receptor agonist refractoriness; bariatric surgery; hepatic steatosis; MASLD; AMPK; pCREB; mitochondrial dysfunction; OXPHOS; weight loss outcomes; biomarker

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Primary source: medrxiv DOI 10.64898/2026.08.04.26359613 (posted 2026-08-06).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• Are OXPHOS defects primary drivers or secondary consequences of broader cellular stress?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on OXPHOS, metabolism, therapeutics, this preprint is worth full-text review soon. Abstract-level takeaway: Objectives To characterize the hepatic histological, ultrastructural, and molecular phenotype of GRO at bariatric surgery, determine its recovery following surgery, and identify preoperative hepatic biomarkers associated with postoperative weight loss. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.